CJC 1295 with DAC half life runs about 6 to 8 days in research, far longer than the 30-minute half-life without DAC. Learn why and how dosing works.
CJC 1295 with DAC has a half-life of roughly 6 to 8 days in human research, with most studies clustering near 7 days. That is far longer than CJC 1295 without DAC, which clears the bloodstream in about 30 minutes. The difference comes from the Drug Affinity Complex (DAC), a chemical modification that lets the peptide bind to albumin and stay in circulation for days instead of minutes.
What CJC 1295 With DAC Actually Is
CJC 1295 is a synthetic version of growth hormone-releasing hormone (GHRH). It contains the first 29 amino acids of GHRH with substitutions designed to resist enzymatic breakdown.
The "with DAC" version adds a maleimide group that binds to albumin, the most abundant protein in blood plasma. Albumin acts as a carrier, so the peptide is released slowly rather than being cleared within minutes.
CJC 1295 with DAC is a research peptide and is not FDA-approved for human use in the United States. It is sold as a research chemical, and no regulatory agency has established a safe or effective human dose.
The CJC 1295 With DAC Half-Life: What Research Reports
Pharmacokinetic studies in healthy adults reported a terminal half-life of roughly 5.8 to 8 days after a single subcutaneous injection. Growth hormone and IGF-1 levels stayed elevated for up to 6 days in those same studies.
Because clearance is measured in days rather than hours, the cjc-1295 half-life is among the longest of any GHRH analog studied so far. That single number shapes almost everything else about how the peptide is handled in research protocols.
| Peptide | Approximate half-life | Typical research frequency |
|---|---|---|
| CJC 1295 with DAC | 6-8 days | Once weekly or every few days |
| CJC 1295 without DAC (Mod GRF 1-29) | ~30 minutes | 1-3 times per day |
| Sermorelin | 10-20 minutes | Daily |
| Ipamorelin | ~2 hours | 1-3 times per day |
Why the DAC Modification Extends the Half-Life
Three things happen once the peptide locks onto albumin.
- Slower kidney clearance. Small peptides are normally filtered out of the blood quickly, but albumin-bound peptides are too large for that filter.
- Protection from enzymes. DPP-4 and other proteases break down free GHRH analogs within minutes, and albumin binding hides the peptide from those enzymes.
- Gradual release. The bond breaks slowly over days, so a small amount of active peptide keeps entering circulation long after the injection.
The result is a sustained rise in growth hormone and IGF-1 rather than the sharp pulses the body produces naturally. Researchers still debate whether that steady elevation is desirable, since healthy growth hormone release happens in bursts.
CJC 1295 With DAC vs CJC 1295 Without DAC
Both versions share the same core sequence but behave very differently in the body. The cjc 1295 no dac half-life is measured in minutes, which is why the two are rarely studied on the same schedule.
| Feature | CJC 1295 with DAC | CJC 1295 without DAC |
|---|---|---|
| Half-life | 6-8 days | ~30 minutes |
| Albumin binding | Yes | No |
| Injections in research | Weekly or less often | 1-3 times daily |
| Growth hormone pattern | Sustained elevation | Short pulse |
| Accumulation risk | Higher | Low |
The two versions are not interchangeable. A weekly dose of CJC 1295 with DAC produces continuous exposure, while the no-DAC version is designed to mimic the body's natural rhythm.
Dosing Frequency in Research Settings
Published research protocols typically use about 1 mg to 2 mg per week of CJC 1295 with DAC, given as one injection or split into two. Those figures come from early clinical studies and should not be read as a recommendation.
Anyone searching for how much cjc 1295 with dac should i take will find wildly conflicting numbers online, and most of them come from forums rather than peer-reviewed data. A cjc-1295 with dac dosage cannot be called safe or verified, because the compound has never been approved for human use.
Because the half-life stretches across days, injections given too close together can stack. That accumulation is one of the main theoretical concerns with weekly use.
Safety, Side Effects, and Legal Status
Reported side effects include injection-site reactions, flushing, headache, fatigue, and water retention. Long-term elevation of IGF-1 is a theoretical concern, since IGF-1 can promote cell growth.
A long half-life also makes side effects harder to manage. A compound that clears in 30 minutes can be stopped quickly, while CJC 1295 with DAC may remain active for a week or more after the last injection.
CJC 1295 with DAC is not approved by the FDA for any human condition and is not a legal prescription medication in the United States. Anyone considering it should speak with a licensed healthcare professional instead of relying on vendor marketing or online anecdotes.
Frequently Asked Questions
How long does CJC 1295 with DAC stay in your system?
CJC 1295 with DAC has a half-life of about 6 to 8 days, so a single dose takes roughly 4 to 6 weeks to clear completely through repeated half-lives. In research settings, growth hormone and IGF-1 elevations were measured for up to 6 days after one injection. Individual clearance depends on factors such as body weight, kidney function, and injection site.
What is the half-life of CJC 1295 without DAC?
CJC 1295 without DAC, often called Mod GRF 1-29, has a half-life of roughly 30 minutes. That short window is why it is studied with multiple daily injections rather than weekly ones. The DAC modification is the main reason the two versions follow such different schedules.
Is CJC 1295 with DAC FDA-approved?
No. CJC 1295 with DAC is not FDA-approved for human use and is sold only as a research chemical in the United States. It is not a legal prescription drug for any medical condition. Anyone with questions about growth hormone-related treatments should consult a licensed healthcare professional.
This page provides educational research information and does not replace medical advice, diagnosis, or treatment.